DSIJ Mindshare

Lupin gets USFDA nod for Sevelamer Hydrochloride tablets for treating chronic kidney disease

Apurva Joshi 0 1230 Article rating: 4.0

Lupin Limited has received approval for its Sevelamer Hydrochloride tablets, 400 mg & 800 mg from United States Food & Drug Administration (USFDA) to market a generic equivalent of Renagel tablets, 400 mg & 800 mg, of Genzyme Corporation. The product will be manufactured at Lupin’s facility in Nagpur (Maharashtra). 

RSS
124678910Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR